Two words you’ll see a lot on this page: indication and contraindication. An indication simply means “this treatment makes sense for this condition.” A contraindication means “don’t do it” — or at least “hold off until something changes.” The catch: there’s no one-size-fits-all list. Whether a treatment is right for you depends on your exact diagnosis, what treatment you’ve already had, your organ function, whether you have an infection, if you’re pregnant, what medicines you’re on, and other factors.[3]
Japan Medical is a health information website. We explain publicly available medical sources — regulatory records, clinical guidelines, research. We are not a hospital, clinic, or treatment provider, and we cannot tell you whether you personally are eligible for a treatment.
“Stem cell therapy” isn’t one thing — it’s a big category. A bone marrow transplant for leukemia has nothing in common with an MSC injection for joint pain. They use different cells, different procedures, and have completely different rules about who should and shouldn’t get them.
Here’s the key point: you can’t take the contraindications from one procedure and apply them to another. You need to know the exact product name, what cells are being used, how they’re processed, the dose, and how they’re going to be given. Until you know those details, the words “indication” and “contraindication” don’t mean much.[5]
This is the one with decades of evidence behind it. It uses blood-forming stem cells, mainly for blood cancers (leukemia, lymphoma, myeloma) and some immune or bone marrow disorders. Eligibility depends on the disease type, whether you have a donor, and whether your body can handle the conditioning chemo.[1]
Mesenchymal stromal cells are being studied for lots of conditions — arthritis, neurological issues, heart repair. But here’s the thing: the evidence level varies hugely from one condition to the next. Just because a clinic offers it doesn’t mean it’s proven to work for your disease.[9]
Some products are designed for one very specific use — like a cell product for a particular type of eye damage. If it’s approved, it’s only approved for that one thing. You can’t assume it works for other problems in the same area of the body.[6]
Cells are grown into thin sheets and applied directly to damaged tissue — think heart muscle or cornea. These are highly specific products, and the rules for one don’t automatically apply to another, even if they affect the same organ.[6]
These are made from reprogrammed adult cells or embryonic stem cells. Most uses are still in clinical trials. If you see a study, the inclusion criteria tell you who can join that specific trial — they’re not a general “this works” stamp.
CAR-T therapy takes your own immune cells, modifies them in a lab, and puts them back to attack cancer. It’s powerful stuff, but it has very strict rules about which diseases, which stage, and what kind of prior treatment qualifies.[5]
Natural killer cells and other immune-cell treatments sometimes get lumped in with stem cell therapy. They’re not the same thing, and the rules about who can get them are totally different.
PRP comes from your own blood — they spin it down and inject the platelet-rich part. It’s not a stem cell product. So the indications and contraindications for stem cells don’t apply here.
The safest starting point is the exact product or procedure name. Evidence, approval, and contraindications for one cell type cannot be transferred to a different product, processing method, route, or condition.[9]
A treatment can have an indication because it’s been proven and approved, or because it’s being studied in a trial. These are not the same thing, and it’s important to know which one you’re looking at.
The treatment is accepted medical practice, or the product has been approved by a regulator like Japan’s PMDA for a specific disease. The approval only covers that exact product and that exact use — nothing else.[5]
A treatment might be offered through a clinical study or under Japan’s provision-plan system. That doesn’t mean it’s a proven, standard treatment. It just means there’s a plan on file saying who can get it under that specific program.[7]
In Japan, two different laws cover this: the PMD Act handles commercial products, and the Act on the Safety of Regenerative Medicine covers research and clinical practice. You need to know which system a treatment falls under before you can understand what its “indication” actually means.[5]
Just saying a condition name isn’t enough. A proper indication spells out the disease, the timing, the product, how it’s given, and who it’s for — all at once.
Here’s what should be in the record you’re looking at:
Two patients with the same broad diagnosis may not share the same indication. Disease status, previous treatment, organ function, infection status, donor factors, and the planned regimen can change eligibility.[3]
First question: does the data support this exact treatment for this exact disease at this point in time? Second question: can your body handle it and the drugs that go with it?
Your exact diagnosis and subtype need to match what the treatment is meant for.
The stage, how active the disease is, and what treatments you’ve already tried all matter.
You’ve looked at the standard options first and understood what happens if you don’t get the cell therapy.
Your organs are working well enough, you don’t have an active infection, and you can commit to the follow-up visits.
HSCT is standard for selected leukemias, lymphomas, multiple myeloma, MDS, and aplastic anaemia. But timing depends on risk level and how the disease responds to other treatments first.[1]
Transplant can help some non-cancer blood and immune disorders. But the decision depends on disease severity, donor match, age, other health problems, and how risky the transplant itself is.[2]
Japan has approved some regenerative products for very specific uses. The approval is for that product, that disease, that dose — you can’t generalize it to other situations.[6]
Just because a treatment has an indication doesn’t mean you qualify. Indication and personal suitability are two separate questions.[3]
These examples show why “stem cells help with X” is way too vague. You need to know the specific treatment, disease stage, and evidence level.
HSCT is standard for certain leukemias, lymphomas, myeloma, and MDS. This is not the same as getting an MSC injection — completely different procedure with completely different rules.[1]
Transplant can work for some patients. But eligibility depends on how severe the disease is, whether a donor is available, your age, other health issues, and the transplant risk itself.[2]
Some bone marrow failure and immune conditions have transplant indications. But criteria depend on the specific disease, donor choice, infection burden, and organ function.
Japan has approved products for specific eye conditions. That approval doesn’t extend to general vision loss, dry eye, or other unrelated eye problems.[6]
A lot of what’s marketed under “stem cell therapy” has limited evidence. The UK’s NICE calls stem cell injections for knee arthritis experimental, and regulators in the US and elsewhere warn against assuming unproven treatments are safe.[11][10]
“Contraindication” isn’t a single thing. It could mean “absolutely no,” or it could mean “only do it if the benefit clearly outweighs the risk,” or it could mean “wait until this other problem is fixed first.”
Don’t do it. The risk is too high or the product documentation says no. Example: the EBMT handbook says pregnancy is an absolute contraindication for hematopoietic cell transplant.[3]
Risk might outweigh benefit, but it depends. Maybe you have an uncontrolled infection, or your liver/kidneys/heart/lungs aren’t working well. The doctor weighs the situation against the available alternatives and decides case by case.[3]
Something needs fixing first — an infection needs treating, a condition needs stabilizing, test results are incomplete. This isn’t a permanent no, just a “come back when this is sorted.”
A diagnosis alone doesn’t decide eligibility. Before treatment, there’s a whole checklist to go through — the disease itself, whether the treatment is likely to help, and what risks the procedure and drugs might create.
Confirm the diagnosis, subtype, stage, previous treatment, current disease control, and whether the exact intervention is supported for that situation.
Review active infections, chronic viral infections, immune suppression, vaccination history, and whether infection control is adequate before treatment.
Assess cardiac function, blood pressure, vascular risk, and whether anaesthesia, conditioning, infusion, or fluid load can be tolerated.
Check respiratory symptoms, imaging, and lung function when the planned treatment can cause pulmonary toxicity or requires intensive conditioning.
Measure organ function because cell processing medicines, conditioning drugs, immunosuppression, and supportive treatment may require dose changes or exclusion.
Review pregnancy or breastfeeding, anticoagulants, immunosuppressants, allergies, interactions, consent, transport, caregiver support, and ability to complete monitoring.
Before hematopoietic stem cell transplantation, standard assessment commonly includes heart tests, chest imaging, blood counts, liver and kidney testing, and confirmation of disease status.[4]
These are screening categories, not a universal no-go list. Whether each one is absolute, relative, or temporary depends on the specific treatment.
The treatment isn’t approved, recommended, or backed by decent evidence for your diagnosis and current condition.
The conditioning drugs and immune suppression that go with treatment can make an infection much worse. For HSCT, this is a relative contraindication — you usually need to get the infection under control first.[3]
If your heart, lungs, liver, or kidneys aren’t working well, the conditioning, anaesthesia, or the treatment itself could be too dangerous. The exact cutoff depends on the procedure.[3]
Pregnancy is an absolute contraindication for HSCT per the EBMT. For other cell products, pregnancy may be a reason to delay or exclude, depending on the drugs, radiation, or anaesthesia involved.[3]
Low platelets, blood thinners, clotting disorders, or anatomy at the injection site can make the procedure unsafe until corrected or worked around.
If your overall health is unstable, you can’t commit to follow-up visits, or there’s no plan for handling complications, treatment may need to wait — even if the disease itself is a valid indication.
These don’t all apply to every treatment. HSCT can cause infection, bleeding, clots, graft-versus-host disease, and organ damage — so the bar for risk is different from a simpler procedure. It always comes down to: does the likely benefit outweigh the risk?[14]
When a doctor decides whether you’re a candidate, that decision should be based on real test results — not just a short symptom checklist or a commercial intake form.[3]
Confirmed diagnosis, subtype, stage or severity, current disease control, prognosis without treatment, and the intended treatment goal.
Prior chemotherapy, radiation, surgery, immunotherapy, transplant, medicines, response, toxicity, and available standard alternatives.
Blood-cell levels, active infection symptoms, relevant viral testing, immune status, and any infection requiring control before treatment.
ECG, echocardiography, imaging, lung function, and other tests required by the planned conditioning, anaesthesia, infusion, or injection route.
Liver and kidney function, electrolytes, coagulation, bleeding or thrombosis risk, allergies, and whether collection and administration are feasible.
Pregnancy or breastfeeding status, interactions, fertility implications, written risks and alternatives, adverse-event plan, costs, caregiver support, and follow-up schedule.
Eight steps you can take before trusting a treatment claim.
Not just “stem cells.” You need the product name, cell source, how it’s processed, dose, how it’s given, and what other drugs go with it.
Your diagnosis, subtype, severity, stage, and what treatments you’ve already had need to match what the treatment is indicated for.
If it’s an approved product in Japan, look up the approved indication, how it’s given, and the listed warnings.[6]
In Japan, a provision plan might show the planned use and consent forms. But this is not the same as PMDA product approval.[8]
Look it up on jRCT or ClinicalTrials.gov. Check who can join, who’s excluded, the study status, and how many people are in it. A registry entry doesn’t mean the treatment works or that the government endorses it.[12][13]
Check your age, overall health, organ function, infection status, pregnancy, medications, donor factors, and prior treatment against the actual eligibility rules.
Some things are permanent no-gos, others are relative risks, and some just mean “fix this first, then we’ll talk.”
A licensed doctor who can examine you needs to decide whether the benefit outweighs the risk. A website, a registry entry, or a brochure can’t make that call.
A proper evaluation looks for reasons not to treat as carefully as it looks for reasons to treat. If someone’s skipping that part, be careful.
The same treatment is claimed to work for lots of different conditions, but nobody can show you disease-specific evidence or criteria for each one.
They don’t ask for records showing your diagnosis, subtype, severity, or what treatments you’ve already tried.
Nobody checks for infections, does blood work, or evaluates your heart, lungs, liver, kidneys. No pregnancy test, no medication review — just straight to treatment.
They can’t or won’t tell you the exact cell source, processing method, dose, route, product name, or study identifier.
Every medical procedure has risks. If someone says everyone is eligible, guarantees results, or claims there are no side effects — be skeptical.[9]
They want payment or travel booked before you’ve seen the consent form, had medical screening, reviewed alternatives, and understood the follow-up plan.
These signs don’t automatically mean something is illegal. They mean the safety checks haven’t been clearly documented yet — and that should make you pause.[10]
Use this checklist to organize your questions before you talk to a licensed physician. We don’t review medical records or decide eligibility.
Exact diagnosis, subtype, disease stage or severity, current symptoms, and objective test results.
Exact product or procedure, cell source, processing, dose, route, treatment schedule, and accompanying drugs.
Guideline, PMDA product record, provision-plan number, study identifier, and whether the use is established, approved, or research-only.
Blood counts, infection status, heart, lungs, liver, kidneys, coagulation, performance status, allergies, and relevant imaging.
Current medicines and supplements, anticoagulants, immune suppression, pregnancy or breastfeeding, and fertility plans.
Standard alternatives, expected benefit, known and unknown risks, complication care, stopping rules, total cost, and follow-up schedule.
No. The rules depend on the exact product, your diagnosis, disease stage, dose, how it’s given, and your overall health. The criteria for a bone marrow transplant can’t be copied to an MSC injection — they’re totally different procedures.[5]
Hematopoietic stem cell transplant is the main one — it’s standard for certain blood cancers and some blood/immune disorders. Beyond that, there are a few approved products in Japan for very narrow uses. A lot of what’s marketed as “stem cell therapy” is still experimental.[1][9]
Usually not, for HSCT at least. The EBMT says age shouldn’t be the only factor. What matters more is your overall health, how the disease is doing, organ function, and what conditioning regimen is planned.[3]
An uncontrolled infection is a relative contraindication for HSCT — meaning treatment usually gets postponed until the infection is under control. Whether this applies to other cell therapies depends on the specific protocol.[3]
For HSCT, yes — pregnancy is an absolute contraindication. For other cell therapies, pregnancy or breastfeeding might mean exclusion or postponement because of the drugs, anaesthesia, or radiation involved.[3]
Yes, they can. Severe organ problems raise the risk significantly. The exact cutoff depends on the procedure — which is why they run tests beforehand to decide whether to go ahead, modify the plan, or wait.[4]
No. PMDA approval covers a specific product for a specific disease. A provision plan is recorded under a different system. Neither one replaces an individual medical evaluation against the actual inclusion and exclusion criteria.[5][7]
We review it when a source we cite changes or when someone sends in a correction that checks out. The last-updated date at the bottom shows the most recent change.
Sources: [1] NCI — Stem Cell and Bone Marrow Transplants for Cancer[2] NHS — Why a Stem Cell or Bone Marrow Transplant Is Done[3] EBMT Handbook — Evaluation and Counseling of Candidates[4] NHS — Preparing for a Stem Cell or Bone Marrow Transplant[5] PMDA — Regenerative Medical Products and Regulatory Framework[6] PMDA — Review Reports for Approved Regenerative Medical Products[7] MHLW — Act on the Safety of Regenerative Medicine[8] MHLW — Published Provision Plans Database[9] ISSCR — Stem Cell Resources for Patients[10] FDA — Patient Information on Regenerative Medicine Therapies[11] NICE — Intra-Articular Stem Cell Injection for Knee Osteoarthritis[12] ClinicalTrials.gov — Official Disclaimer[13] jRCT — Japan Registry of Clinical Trials[14] NHS — Complications of Stem Cell or Bone Marrow Transplant
Ask us about terminology, PMDA product records, provision plans, trial criteria, or any source cited on this page. Please don’t send medical records, test results, or other personal health information.
Japan Medical explains public sources; we are not a medical provider.
